Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcomeCitation formats

  • External authors:
  • Melanie Green
  • Melanie M L Green
  • Crispin T. Hiley
  • Jonathan H. Shanks
  • Ian C. Bottomley
  • Richard A. Cowan

Standard

Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome. / Green, Melanie; Green, Melanie M L; Hiley, Crispin T.; Shanks, Jonathan H.; Bottomley, Ian C.; West, Catharine M L; Cowan, Richard A.; Stratford, Ian J.

In: International Journal of Radiation Oncology Biology Physics, Vol. 67, No. 1, 01.01.2007, p. 84-90.

Research output: Contribution to journalArticlepeer-review

Harvard

Green, M, Green, MML, Hiley, CT, Shanks, JH, Bottomley, IC, West, CML, Cowan, RA & Stratford, IJ 2007, 'Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome', International Journal of Radiation Oncology Biology Physics, vol. 67, no. 1, pp. 84-90. https://doi.org/10.1016/j.ijrobp.2006.08.077

APA

Green, M., Green, M. M. L., Hiley, C. T., Shanks, J. H., Bottomley, I. C., West, C. M. L., Cowan, R. A., & Stratford, I. J. (2007). Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome. International Journal of Radiation Oncology Biology Physics, 67(1), 84-90. https://doi.org/10.1016/j.ijrobp.2006.08.077

Vancouver

Green M, Green MML, Hiley CT, Shanks JH, Bottomley IC, West CML et al. Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome. International Journal of Radiation Oncology Biology Physics. 2007 Jan 1;67(1):84-90. https://doi.org/10.1016/j.ijrobp.2006.08.077

Author

Green, Melanie ; Green, Melanie M L ; Hiley, Crispin T. ; Shanks, Jonathan H. ; Bottomley, Ian C. ; West, Catharine M L ; Cowan, Richard A. ; Stratford, Ian J. / Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome. In: International Journal of Radiation Oncology Biology Physics. 2007 ; Vol. 67, No. 1. pp. 84-90.

Bibtex

@article{d226fd06270d4aed983227379b0cd5c8,
title = "Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome",
abstract = "Purpose: Vascular endothelial growth factor (VEGF) is an important hypoxia-inducible pro-angiogenic protein that has been linked with an adverse survival outcome after radiotherapy in other cancer types: we hypothesized that this may also occur in prostate cancer. A retrospective study was, therefore, carried out to evaluate the potential of tumor VEGF expression to predict radiotherapy outcome in patients with high-risk prostate cancer. Methods and Materials: Fifty patients with locally advanced (T3 N0 M0) tumors of Gleason score ≥6, and who received radiotherapy alone as primary treatment for their disease, were studied. Vascular endothelial growth factor expression was assessed on pretreatment diagnostic tumor biopsies using a semiquantitative immunohistochemical scoring system. The results were analyzed in relation to clinicopathologic factors and patient outcome including biochemical failure and disease-specific mortality. Results: High VEGF expression was associated with a poor prognosis: in univariate log rank analysis, VEGF was the only significant prognostic factor for disease-specific survival (p = 0.035). High VEGF expression also associated with increased Gleason score (p = 0.02), but not posttreatment biochemical failure. Conclusion: High tumor expression of VEGF identified patients at high risk of failure of treatment with radiotherapy. These patients might benefit from additional treatment approaches incorporating anti-angiogenic or hypoxia-specific agents. {\textcopyright} 2007 Elsevier Inc. All rights reserved.",
keywords = "Prognosis, Prostate cancer, Radiotherapy, Vascular endothelial growth factor",
author = "Melanie Green and Green, {Melanie M L} and Hiley, {Crispin T.} and Shanks, {Jonathan H.} and Bottomley, {Ian C.} and West, {Catharine M L} and Cowan, {Richard A.} and Stratford, {Ian J.}",
year = "2007",
month = jan,
day = "1",
doi = "10.1016/j.ijrobp.2006.08.077",
language = "English",
volume = "67",
pages = "84--90",
journal = "International Journal of Radiation: Oncology - Biology - Physics",
issn = "0360-3016",
publisher = "Elsevier BV",
number = "1",

}

RIS

TY - JOUR

T1 - Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome

AU - Green, Melanie

AU - Green, Melanie M L

AU - Hiley, Crispin T.

AU - Shanks, Jonathan H.

AU - Bottomley, Ian C.

AU - West, Catharine M L

AU - Cowan, Richard A.

AU - Stratford, Ian J.

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Purpose: Vascular endothelial growth factor (VEGF) is an important hypoxia-inducible pro-angiogenic protein that has been linked with an adverse survival outcome after radiotherapy in other cancer types: we hypothesized that this may also occur in prostate cancer. A retrospective study was, therefore, carried out to evaluate the potential of tumor VEGF expression to predict radiotherapy outcome in patients with high-risk prostate cancer. Methods and Materials: Fifty patients with locally advanced (T3 N0 M0) tumors of Gleason score ≥6, and who received radiotherapy alone as primary treatment for their disease, were studied. Vascular endothelial growth factor expression was assessed on pretreatment diagnostic tumor biopsies using a semiquantitative immunohistochemical scoring system. The results were analyzed in relation to clinicopathologic factors and patient outcome including biochemical failure and disease-specific mortality. Results: High VEGF expression was associated with a poor prognosis: in univariate log rank analysis, VEGF was the only significant prognostic factor for disease-specific survival (p = 0.035). High VEGF expression also associated with increased Gleason score (p = 0.02), but not posttreatment biochemical failure. Conclusion: High tumor expression of VEGF identified patients at high risk of failure of treatment with radiotherapy. These patients might benefit from additional treatment approaches incorporating anti-angiogenic or hypoxia-specific agents. © 2007 Elsevier Inc. All rights reserved.

AB - Purpose: Vascular endothelial growth factor (VEGF) is an important hypoxia-inducible pro-angiogenic protein that has been linked with an adverse survival outcome after radiotherapy in other cancer types: we hypothesized that this may also occur in prostate cancer. A retrospective study was, therefore, carried out to evaluate the potential of tumor VEGF expression to predict radiotherapy outcome in patients with high-risk prostate cancer. Methods and Materials: Fifty patients with locally advanced (T3 N0 M0) tumors of Gleason score ≥6, and who received radiotherapy alone as primary treatment for their disease, were studied. Vascular endothelial growth factor expression was assessed on pretreatment diagnostic tumor biopsies using a semiquantitative immunohistochemical scoring system. The results were analyzed in relation to clinicopathologic factors and patient outcome including biochemical failure and disease-specific mortality. Results: High VEGF expression was associated with a poor prognosis: in univariate log rank analysis, VEGF was the only significant prognostic factor for disease-specific survival (p = 0.035). High VEGF expression also associated with increased Gleason score (p = 0.02), but not posttreatment biochemical failure. Conclusion: High tumor expression of VEGF identified patients at high risk of failure of treatment with radiotherapy. These patients might benefit from additional treatment approaches incorporating anti-angiogenic or hypoxia-specific agents. © 2007 Elsevier Inc. All rights reserved.

KW - Prognosis

KW - Prostate cancer

KW - Radiotherapy

KW - Vascular endothelial growth factor

U2 - 10.1016/j.ijrobp.2006.08.077

DO - 10.1016/j.ijrobp.2006.08.077

M3 - Article

VL - 67

SP - 84

EP - 90

JO - International Journal of Radiation: Oncology - Biology - Physics

JF - International Journal of Radiation: Oncology - Biology - Physics

SN - 0360-3016

IS - 1

ER -